Gene signatures of early response to anti-TNF drugs in pediatric inflammatory bowel disease
Author
Salvador-Martín, Sara; Raposo-Gutiérrez, Irene; Navas-López, Víctor Manuel; Gallego-Fernández, Carmen; Moreno-Álvarez, Ana; Solar-Boga, Alfonso; Muñoz Codoceo, Rosa Ana; Magallares, Lorena; Martínez-Ojinaga, Eva; Fobelo, María J.; Millán-Jiménez, Antonio; Rodriguez-Martinez, Alejandro; Vayo, Concepción A.; Sánchez, Cesar; Tolin, Mar; Bossacoma, Ferrán; Pujol-Muncunill, Gemma; González de Caldas, Rafael; Loverdos, Inés; Blanca-García, José A.; Segarra, Oscar; Eizaguirre, Francisco J.; García-Romero, Ruth; Merino-Bohórquez, Vicente; Sanjurjo-Sáez, María; López-Fernández, Luis A.Entity
UAM. Departamento de Pediatría; Instituto de Investigación Sanitaria Hospital Universitario de La Princesa (IIS-IP)Publisher
MDPI, Basel, SMwitzerlandDate
2020-05-09Citation
10.3390/ijms21093364
International Journal of Molecular Sciences 21.9 (2020): 3364
ISSN
1661-6596DOI
10.3390/ijms21093364Funded by
This work was funded by Instituto de Salud Carlos III (grants numbers PI16/00559 and PI19/00792), Consejería de Educación y Deporte de la Comunidad de Madrid (grant number PEJ16/MED/AI-1260), and by the Gregorio Marañón Health Research Institute (grant number PRE-2018-2), The study was cofunded by ERDF Funds (FEDER) from the European Commission, “A way of making Europe”Project
Gobierno de España. PI16/00559; Gobierno de España. PI19/00792Editor's Version
http://doi.org/10.3390/ijms21093364Subjects
Adalimumab; Biomarker; Crohn’s disease; Gene expression; Infliximab; Ulcerative colitis; MedicinaRights
© 2020 The AuthorsAbstract
T. Around a 20–30% of inflammatory bowel disease (IBD) patients are diagnosed before they are 18 years old. Anti-TNF drugs can induce and maintain remission in IBD, however, up to 30% of patients do not respond. The aim of the work was to identify markers that would predict an early response to anti-TNF drugs in pediatric patients with IBD. The study population included 43 patients aged <18 years with IBD who started treatment with infliximab or adalimumab. Patients were classified into primary responders (n = 27) and non-responders to anti-TNF therapy (n = 6). Response to treatment could not be analyzed in 10 patients. Response was defined as a decrease in over 15 points in the disease activity indexes from week 0 to week 10 of infliximab treatment or from week 0 to week 26 of adalimumab treatment. The expression profiles of nine genes in total RNA isolated from the whole-blood of pediatric IBD patients taken before biologic administration and after 2 weeks were analyzed using qPCR and the 2−∆∆Ct method. Before initiation and after 2 weeks of treatment the expression of SMAD7 was decreased in patients who were considered as non-responders (p value < 0.05). Changes in expression were also observed for TLR2 at T0 and T2, although that did not reach the level of statistical significance. In addition, the expression of DEFA5 decreased 1.75-fold during the first 2 weeks of anti-TNF treatment in responders, whereas no changes were observed in non-responders. Expression of the SMAD7 gene is a pharmacogenomic biomarker of early response to anti-TNF agents in pediatric IBD. TLR2 and DEFA5 need to be validated in larger studies.
Files in this item
Google Scholar:Salvador-Martín, Sara
-
Raposo-Gutiérrez, Irene
-
Navas-López, Víctor Manuel
-
Gallego-Fernández, Carmen
-
Moreno-Álvarez, Ana
-
Solar-Boga, Alfonso
-
Muñoz Codoceo, Rosa Ana
-
Magallares, Lorena
-
Martínez-Ojinaga, Eva
-
Fobelo, María J.
-
Millán-Jiménez, Antonio
-
Rodriguez-Martinez, Alejandro
-
Vayo, Concepción A.
-
Sánchez, Cesar
-
Tolin, Mar
-
Bossacoma, Ferrán
-
Pujol-Muncunill, Gemma
-
González de Caldas, Rafael
-
Loverdos, Inés
-
Blanca-García, José A.
-
Segarra, Oscar
-
Eizaguirre, Francisco J.
-
García-Romero, Ruth
-
Merino-Bohórquez, Vicente
-
Sanjurjo-Sáez, María
-
López-Fernández, Luis A.
This item appears in the following Collection(s)
Related items
Showing items related by title, author, creator and subject.
-
Genetic landscape of 6089 inherited retinal dystrophies affected cases in Spain and their therapeutic and extended epidemiological implications
Perea-Romero, Irene; Gordo, Gema; Iancu, Ionut F.; Del Pozo-Valero, Marta; Almoguera, Berta; Blanco-Kelly, Fiona; Carreño, Ester; Jimenez-Rolando, Belen; Lopez-Rodriguez, Rosario; Lorda-Sanchez, Isabel; Martin-Merida, Inmaculada; Pérez de Ayala, Lucia; Riveiro-Alvarez, Rosa; Rodriguez-Pinilla, Elvira; Tahsin-Swafiri, Saoud; Trujillo-Tiebas, Maria J.; Bustamante-Aragones, Ana; Cardero-Merlo, Rocio; Fernandez-Sanchez, Ruth; Gallego-Merlo, Jesus; Garcia-Vara, Ines; Gimenez-Pardo, Ascension; Horcajada-Burgos, Laura; Infantes-Barbero, Fernando; Lantero, Esther; Lopez-Martinez, Miguel A.; Martinez-Ramas, Andrea; Ondo, Lorena; Rodriguez de Alba, Marta; Sanchez-Jimeno, Carolina; Velez-Monsalve, Camilo; Villaverde, Cristina; Zurita, Olga; Aguilera-Garcia, Domingo; Aguirre-Lamban, Jana; Arteche, Ana; Cantalapiedra, Diego; Fernandez-San Jose, Patricia; Galbis-Martinez, Liliana; Garcia-Hoyos, Maria; Lombardia, Carlos; Lopez-Molina, Maria I.; Perez-Carro, Raquel; Da Silva, Luciana R.J.; Ramos, Carmen; Sanchez-Alcudia, Rocio; Sanchez-Navarro, Iker; Tatu, Sorina D.; Vallespin, Elena; Aller, Elena; Bernal, Sara; Gamundi, Maria J.; Garcia-Garcia, Gema; Hernan, Inmaculada; Jaijo, Teresa; Antiñolo, Guillermo; Baiget, Montserrat; Carballo, Miguel; Millan, Jose M.; Valverde, Diana; Allikmets, Rando; Banfi, Sandro; Cremers, Frans P.M.; Collin, Rob W.J.; De Baere, Elfride; Hakonarson, Hakon; Kohl, Susanne; Rivolta, Carlo; Sharon, Dror; Alonso-Cerezo, Maria C.; Ballesta-Martinez, Maria J.; Beltran, Sergi; Benito Lopez, Carmen; Català-Mora, Jaume; Catalli, Claudio; Cotarelo-Perez, Carmen; Fernandez-Burriel, Miguel; Fontalba-Romero, Ana; Galán-Gómez, Enrique; Garcia-Barcina, Maria; Garcia-Cruz, Loida M.; Gener, Blanca; Gil-Fournier, Belen; Govea, Nancy; Guillen-Navarro, Encarna; Hernando Acero, Ines; Irigoyen, Cristina; Izquierdo-Álvarez, Silvia; Llano-Rivas, Isabel; López-Ariztegui, Maria A.; Lopez-Gonzalez, Vanesa; Lopez-Grondona, Fermina; Martorell, Loreto; Mendez-Perez, Pilar; Moreno-Igoa, Maria; Oancea-Ionescu, Raluca; Palau-Martinez, Francesc; Perez de Nanclares, Guiomar; Ramos-Fuentes, Feliciano J.; Rodriguez-Lopez, Raquel; Ayuso García, María del Carmen Tomasa
2021-12-01 -
Body mass index and disease activity in chronic inflammatory rheumatic diseases: Results of the cardiovascular in rheumatology (CARMA) project
Valero-Jaimes, Jesús A.; López-González, Ruth; Martín-Martínez, María A.; García-Gómez, Carmen; Sánchez-Alonso, Fernando; Sánchez-Costa, Jesús T.; González-Juanatey, Carlos; Revuelta-Evrad, Eva; Díaz-Torné, César; Fernández-Espartero, Cruz; Pérez-García, Carolina; Torrente-Segarra, Vicenç; Sánchez-Nievas, Ginés; Pérez-Sandoval, Trinidad; Font-Ugalde, Pilar; García-Vivar, María L.; Aurrecoechea, Elena; Maiz-Alonso, Olga; Valls-García, Ramón; Miranda-Filloy, José A.; Llorca, Javier; Castañeda Sanz, Santos; Gonzalez-Gay, Miguel A.; CARMA Study Group
2021-01-20 -
Changes in the requirement for early surgery in inflammatory bowel disease in the era of biological agents
Guasch, Montserrat; Cañete, Fiorella; Ordás, Ingrid; Iglesisas-Flores, Eva; Clos, Ariadna; Pérez Gisbert, Francisco Javier; Taxonera, Carlos; Vera Mendoza, María Isabel; Mínguez, Miguel; Guardiola, Jordi; Rivero, Montserrat; Nos, Pilar; Gomollón, Fernando; Barrio, Jesús; Francisco, Ruth de; López-Sanromán, Antonio; Martín Arranz, María Dolores; García Planella, Esther; Camargo, Raquel; García-López, Santiago; Castro, Luisa de; Calvet, Xavier; Esteve, María; Mañosa, Miriam; Doménech, Eugeni
2020-04-29